RAF / KIN-2787 Combination

Our lead RAF program, KIN 2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations (Class II and Class III) that characterize subsets of melanoma, lung cancer, and other solid tumors. As a pan-RAF kinase inhibitor, KIN-2787...